Minor bleeding · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis probably leads to higher minor bleeding compared with low molecular weight heparin secondary prophylaxis (moderate certainty).
1 finding from 1 review
Minor GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes minor GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
Minor upper GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes minor upper GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
Minor lower GI bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor lower GI bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Minor non‐GI bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis probably leads to higher minor non‐GI bleeding compared with low molecular weight heparin secondary prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · people with cancer with VTE receiving secondary prophylaxis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).
1 finding from 1 review
Intervention not reported
Minor adverse events · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Adeno carcinoma in situ (AIS) associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower adeno carcinoma in situ (AIS) associated with HPV16/18 (high certainty).
1 finding from 1 review
Minor bleeding · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in minor Bleeding compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in minor bleeding compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Severe (defined as stage 3 or greater) retinopathy of prematurity ‐ not reported · preterm infants
Lower showed no clear difference in severe retinopathy of prematurity (≥ stage 3) compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Minor adverse events assessed: related to intervention only (e.g. redness) · COPD
1 finding from 1 review
Minor adverse events assessed: related to intervention only (e.g. redness) · COPD
NMES showed no clear difference in minor adverse events assessed: related to intervention only (e.g.… compared with usual care (with or without sham NMES) (low certainty).
1 finding from 1 review
Overall survival ‐ FOLFIRINOX · advanced pancreatic cancer
Various types of chemotherapy probably leads to lower overall survival ‐ FOLFIRINOX compared with gemcitabine (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ minor Infections Clinical events experienced by children during the 1 year period commencing at entry to the trial · 117 children with homozygous sickle cell (SS) disease
The intervention showed no clear difference in adverse events ‐ minor Infections Clinical events experienced by… (low certainty).
1 finding from 1 review
Secondary outcome: achievement of binocular single vision · people with sixth nerve palsy
Botulinum toxin showed no clear difference in achievement of binocular single vision (fusion and stereopsis… compared with observation (low certainty).
1 finding from 1 review
Hepatocellular carcinoma · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Survival time from onset of inoperable MBO until death. · Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found